InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,572.85
(
0.10%
)
US TECH 100
19,974.00
(
0.40%
)
Dow Jones
39,344.79
(
-0.08%
)
Brent Oil
85.13
(
-0.34%
)
Bitcoin
57,603.61
(
1.58%
)
Post# of 252526
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 831
Posts 119993
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: jbog post# 100784

Thursday, 08/05/2010 2:03:11 PM

Thursday, August 05, 2010 2:03:11 PM

Post# of 252526
Does anyone here care to comment on Xarelto? It’s a potentially consequential drug for several companies—not just for JNJ and Bayer—and it’s an especially hard program to handicap, IMO.

Here are a few posts for background reading in case anyone is interested:

#msg-38200098 FDA issues CRL (no response submitted yet)
#msg-44245112 Safety signal in EINSTEIN-EXT study
#msg-34103973 Phase-3 data in VTE prevention
#msg-39151366 Xarelto prospects in ACS

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up